ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BGLC vs AMS // EV/EBITDA & P/E VALUATION

BioNexus Gene Lab Corp (NASDAQ) VS. American Shared Hospital Services (NYSE) • 15-METRIC TALLY: BGLC 1 — AMS 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BGLC VS. AMS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BGLC AMS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 14.60% 18.00% -3.40 AMS /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -13.80% -21.20 AMS /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -39.90% -12.80% -27.10 AMS /operating-margins <GO>
Net Profit Margin -40.20% -5.50% -34.70 AMS /net-margins <GO>
Revenue Growth (YoY) -21.90% -0.90% -21.00 AMS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.12 0.46 +1.66 BGLC /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 AMS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 24.5 42.0 -17.54 AMS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.9M $8.4M -$5.5M AMS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BGLC REV AMS REV BGLC GROSS % AMS GROSS % BGLC FCF AMS FCF
FY 2025 $7.4M $28.1M 14.6% 18.0% -$1.9M -$4.5M
FY 2024 $9.5M $28.3M 13.6% 32.4% -$2.3M -$7.8M
FY 2023 $9.8M $21.3M — — -$1.8M $5.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BGLC // BETA —
AMS // BETA —